ATE229029T1 - 2'-geschützter 3'-dimethylamin, 9-etheroxim erythromycin a derivate - Google Patents

2'-geschützter 3'-dimethylamin, 9-etheroxim erythromycin a derivate

Info

Publication number
ATE229029T1
ATE229029T1 AT97905824T AT97905824T ATE229029T1 AT E229029 T1 ATE229029 T1 AT E229029T1 AT 97905824 T AT97905824 T AT 97905824T AT 97905824 T AT97905824 T AT 97905824T AT E229029 T1 ATE229029 T1 AT E229029T1
Authority
AT
Austria
Prior art keywords
erythromycin
etheroxime
protected
derivatives
dimethylamine
Prior art date
Application number
AT97905824T
Other languages
English (en)
Inventor
Chengxi Yang
Hemantkumar H Patel
Yi-Kin Ku
Jih-Hua Liu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE229029T1 publication Critical patent/ATE229029T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97905824T 1996-04-02 1997-02-06 2'-geschützter 3'-dimethylamin, 9-etheroxim erythromycin a derivate ATE229029T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/627,795 US5719272A (en) 1996-04-02 1996-04-02 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
PCT/US1997/001952 WO1997036912A1 (en) 1996-04-02 1997-02-06 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin a derivatives

Publications (1)

Publication Number Publication Date
ATE229029T1 true ATE229029T1 (de) 2002-12-15

Family

ID=24516163

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905824T ATE229029T1 (de) 1996-04-02 1997-02-06 2'-geschützter 3'-dimethylamin, 9-etheroxim erythromycin a derivate

Country Status (9)

Country Link
US (1) US5719272A (de)
EP (1) EP0891370B1 (de)
JP (1) JP4116674B2 (de)
AT (1) ATE229029T1 (de)
DE (1) DE69717613T2 (de)
DK (1) DK0891370T3 (de)
ES (1) ES2188896T3 (de)
PT (1) PT891370E (de)
WO (1) WO1997036912A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69730138T2 (de) 1996-07-29 2005-03-03 Abbott Laboratories, Abbott Park Herstellung von kristallinen form ii von clarithromycin
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
AP1060A (en) * 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
KR100317907B1 (ko) * 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
AR023264A1 (es) * 1999-04-08 2002-09-04 Hokuriku Pharmaceutical Derivados de eritromicina
HUP0201516A3 (en) 1999-05-24 2003-03-28 Pfizer Prod Inc 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
GB9915745D0 (en) * 1999-07-06 1999-09-08 Biochemie Sa Organic compounds
WO2001044262A1 (en) 1999-12-16 2001-06-21 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph iv
AU2261901A (en) 2000-01-11 2001-07-24 Teva Pharma Processes for preparing clarithromycin polymorphs
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
KR20030047873A (ko) * 2000-02-29 2003-06-18 테바 파마슈티컬 인더스트리즈 리미티드 클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
AU2002357482B2 (en) * 2001-11-07 2009-03-26 Sanofi-Aventis Deutschland Gmbh Method for the production of desclarithromycin, and intermediate products
EP1638549A4 (de) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc Neue antibakterielle mittel
US7435805B2 (en) 2003-05-30 2008-10-14 Glaxpsmithkline Istrazivacki O-alkyl macrolide and azalide derivatives and regioselective process for their preparation
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258953B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2535177A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) * 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
CA2572292A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US7595300B2 (en) 2005-12-13 2009-09-29 Kosan Biosciences Incorporated 7-quinolyl ketolide antibacterial agents
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
GB0616865D0 (en) * 2006-08-25 2007-03-28 Phoenix Chemicals Ltd Process
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
EP2214484A4 (de) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc Verfahren zur herstellung von antibakteriellen makrolid-wirkstoffen
JP5711135B2 (ja) 2008-10-24 2015-04-30 センプラ ファーマシューティカルズ,インコーポレイテッド 胃腸疾患を治療するための方法
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
EP2613630A4 (de) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc Wasserstoffbindung zur formung von fluorketoliden zur behandlung von krankheiten
NZ700182A (en) 2012-03-27 2017-02-24 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
AU2014239959A1 (en) 2013-03-14 2015-10-01 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
CN105188712A (zh) 2013-03-15 2015-12-23 森普拉制药公司 用于制备大环内酯抗菌剂的收敛方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd 6−0−メチルエリスロマイシン類の製法
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
EP0260938B1 (de) * 1986-09-18 1992-12-09 Taisho Pharmaceutical Co. Ltd Erythromycin-A-Derivate und Verfahren zu ihrer Herstellung
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
US5350839A (en) * 1990-10-15 1994-09-27 Taisho Pharmaceutical Co., Ltd. 2'-position modified compound of erythromycin or its derivative

Also Published As

Publication number Publication date
DK0891370T3 (da) 2003-03-24
US5719272A (en) 1998-02-17
WO1997036912A1 (en) 1997-10-09
DE69717613T2 (de) 2003-09-18
DE69717613D1 (en) 2003-01-16
PT891370E (pt) 2003-04-30
JP4116674B2 (ja) 2008-07-09
JP2000507573A (ja) 2000-06-20
EP0891370B1 (de) 2002-12-04
ES2188896T3 (es) 2003-07-01
EP0891370A1 (de) 1999-01-20

Similar Documents

Publication Publication Date Title
ATE229029T1 (de) 2'-geschützter 3'-dimethylamin, 9-etheroxim erythromycin a derivate
CA2279932A1 (en) 3'-n-oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
AP9801253A0 (en) 9-Oxime erythromycin derivatives.
CA2354774A1 (en) Farnesyl protein transferase inhibitors
DK1044209T3 (da) Fremgangsmåde till fremstilling af 6-O-methylerythromycin A ved at anvende derivater af 9-hydroxyerythromycin
BG42675A3 (bg) Метод за получаване на 20-амино-макролидни производни
AU2555592A (en) Method for synthesizing glucuronides of 4,5-epoxy morphinanes
ZA966601B (en) Process for producing erythromycin derivatives.
CA2264513A1 (en) Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
FI953841L (fi) Substituoituja kinoliinijohdannaisia, menetelmä niiden valmistamseksi
DK0784605T3 (da) Selektiv fremgangsmåde til deacyleringen af acylforbindelser
CA2250736A1 (en) 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin a derivatives
HUP9900377A3 (en) Novel process for preparing 2,3-dihydro-benzofuranol derivatives
FR2749585B1 (fr) Nouveaux derives aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments
PL315422A1 (en) Novel compounds and their salts, method of obtaining them as well as pharmaceutic agent and method of obtaining same
PL327581A1 (en) Method of selectively protecting bacatin derivatives and application thereof in a process of synthesising taxanes
NZ335325A (en) Erythromycin derivatives, method for preparing them and their use as medicine
CA2195975A1 (en) An improved process for preparing side chain derivatives of cyclohexapeptidyl lipopeptides
ATE354580T1 (de) Oleandomycin-derivate
MY133929A (en) A cost effective method for selective methylation of erythromycin a derivatives
PL315707A1 (en) Novel compounds and their salts, method of obtaining them as well as pharmaceutic preparation and method of obtaining same
WO2001012642A3 (de) Nucleosidderivate und verfahren zu deren herstellung
IL123386A0 (en) 3-Deoxy-3-descladinose derivatives of erythromycins
DE69218005D1 (de) 2'-deoxy-2'-fluorcoformycin und stereoisomere davon
DE69601451D1 (de) UCK14-Verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0891370

Country of ref document: EP

REN Ceased due to non-payment of the annual fee